These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 34912478)

  • 1. Matching-adjusted indirect treatment comparison of [
    Khan MS; Stamp E; Sammon C; Brabander T; de Herder WW; Pavel ME
    EJC Suppl; 2021 Nov; 16():5-13. PubMed ID: 34912478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of [
    Glover M; Caplin M; Leeuwenkamp OR; Longworth L
    EJC Suppl; 2021 Nov; 16():14-23. PubMed ID: 34912479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Spada F; Campana D; Lamberti G; Laudicella R; Dellamano R; Dellamano L; Leeuwenkamp O; Baldari S
    Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2037-2048. PubMed ID: 34950969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lutetium oxodotreotide (
    Smith-Palmer J; Leeuwenkamp OR; Virk J; Reed N
    BMC Cancer; 2021 Jan; 21(1):10. PubMed ID: 33402120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lutetium [
    Lastoria S; Rodari M; Sansovini M; Baldari S; D'Agostini A; Cervino AR; Filice A; Salgarello M; Perotti G; Nieri A; Campana D; Pellerito RE; Pomposelli E; Gaudieri V; Storto G; Grana CM; Signore A; Boni G; Dondi F; Simontacchi G; Seregni E
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3417-3427. PubMed ID: 38772998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world comparison of healthcare resource utilization and costs of [
    Cox T; O'Connell M; Leeuwenkamp O; Palimaka S; Reed N
    Curr Med Res Opin; 2022 Aug; 38(8):1305-1317. PubMed ID: 35418254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [
    Zellmer J; Yen HY; Kaiser L; Mille E; Gildehaus FJ; Böning G; Steiger K; Hacker M; Bartenstein P; Todica A; Haug AR; Ilhan H
    EJNMMI Res; 2020 Apr; 10(1):41. PubMed ID: 32335736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of [
    Hertelendi M; Belguenani O; Cherfi A; Folitar I; Kollar G; Polack BD
    Biomedicines; 2023 Mar; 11(4):. PubMed ID: 37189646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of lutetium (
    Palmer J; Leeuwenkamp OR
    World J Clin Cases; 2020 Oct; 8(20):4793-4806. PubMed ID: 33195647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors.
    Zellmer J; Yen HY; Kaiser L; Gildehaus FJ; Böning G; Steiger K; Hacker M; Bartenstein P; Todica A; Haug AR; Ilhan H
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-treatment with [177Lu]Lu-DOTA-TATE or [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE of patients with progressive neuroendocrine neoplasm.
    Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Mróz A; Kapusta W; Dmochowska B; Kamiński G
    Nucl Med Rev Cent East Eur; 2023; 26(0):143-152. PubMed ID: 38966954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [
    Durma AD; Saracyn M; Kołodziej M; Jóźwik-Plebanek K; Dmochowska B; Kapusta W; Żmudzki W; Mróz A; Kos-Kudła B; Kamiński G
    Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
    Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
    Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
    Seregni E; Maccauro M; Chiesa C; Mariani L; Pascali C; Mazzaferro V; De Braud F; Buzzoni R; Milione M; Lorenzoni A; Bogni A; Coliva A; Lo Vullo S; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):223-30. PubMed ID: 24233003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of [
    Ha S; Kim YI; Oh JS; Yoo C; Ryoo BY; Ryu JS
    EJNMMI Phys; 2024 Feb; 11(1):14. PubMed ID: 38315270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing [
    Cheng J; Zink J; O'Neill E; Cornelissen B; Nonnekens J; Livieratos L; Terry SYA
    EJNMMI Res; 2024 Aug; 14(1):73. PubMed ID: 39136880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the effectiveness and safety of surufatinib versus everolimus or sunitinib in advanced neuroendocrine neoplasms: insights from a real-world, retrospective cohort study using propensity score and inverse probability treatment weighting analysis.
    Zhu L; Ye X; She Y; Liu W; Hasegawa K; Rossi RE; Du Q; Zhai Q
    J Gastrointest Oncol; 2024 Apr; 15(2):689-709. PubMed ID: 38756630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.